礼邦医药(Alebund Pharmaceuticals,江苏)宣布,国家药品监督管理局(NMPA)已正式受理其AP301胶囊的新药上市申请(NDA)。该药针对慢性肾病患者透析过程中出现的高磷血症。这一里程碑事件,标志着其研发取得关键进展。
礼邦医药(Alebund Pharmaceuticals,江苏)宣布,国家药品监督管理局(NMPA)已正式受理其AP301胶囊的新药上市申请(NDA)。该药针对慢性肾病患者透析过程中出现的高磷血症。这一里程碑事件,标志着其研发取得关键进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.